Sustained response after 1 year of treatment with interferon, alone or combined with ribavirin, in positive hepatitis C virus cirrhotic patients

• Autor(a) principal: Cheinquer, Hugo
• Data de Publicação: 2022
• Outros Autores: C. Borges, Silvia, Ariente, Samara, Garcia, Régis, Ikuta, Nilo, Lunge, Vagner, Fonseca, André
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Clinical and Biomedical Research
• Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/124811
• topic: HCV virus; cirrhoris; interferon treatment; ribavirin treatment; Cirrose; VHC; ; tratamento com interferon; tratamento com interferon e ribavirina

OBJECTIVE: The objective of this study was to assess the rate of end of treatmentcomplete response and sustained response in positive HCV cirrhotic patients thatwere either treated with interferon only, or with interferon in combination with ribavirin.PATIENTS AND METHODS: A total of 33 ambulatory HCV-positive cirrhotic patients,without any other identifiable etiology of liver disease and classified as Child-Pugh Awere divided in a non-randomized manner into the following groups: Group 1 (n=13),treated with subcutaneous doses of interferon (3 UM), three times per week, for 12months; Group 2 (n=20), treated with the same interferon schedule as describedabove, though associated with oral ribavirin (1000 mg/day) twice a day for 12 months.Among the 33 patients, 24 (73%) were male, and the age of all patients ranged from35 to 72 years (mean of 50.7 + 9 years).RESULTS: The rate of end of treatment complete response and of sustained responsefor Group 1 was 1/13 (8%) and 0/13 (0%) respectively, versus 11/20 (55%) and 7/20(35%) for Group 2 (P<0.005). The groups did not differ significantly with respect toage, sex, serum, serum ferritin, gamaglutamyl-transpeptidase, estimated diseaseduration, degree of necro-inflammatory activity, and HCV genotype. Upon comparingpatients that did not present a sustained response (n=26) with patients that didpresent a sustained response (n=7), we observed that the only predictor of sustainedresponse with statistical significance was the type of treatment employed (P<0.002).CONCLUSIONS: Ambulatory patients with compensated cirrhosis caused by theHCV, when submitted to the interferon and ribavirin treatment for 1 year, presenteda statistically significant higher rate of sustained response than patients submittedto the interferon only treatment for the same period of time. There was no statisticallysignificant difference between the groups in terms of frequency of side-effects.